Previous 10 | Next 10 |
Cybin (NYSE American: CYBN) (Cboe CA: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative next-generation psychedelic treatment options, today announced unaudited financial results for its third quarter ended Dec. 31,...
2024-02-14 07:59:11 ET More on Cybin De-Risking Psychedelics: Compass Pathways, Cybin And Atai Psychedelic stocks gain after FDA priority review for MDMA therapy Cybin reports Japan grant of additional patents for anxiety disorder treatment Seeking Alpha ...
- Reported positive Phase 2 topline results for CYB003, its proprietary deuterated psilocybin analog in development for the adjunctive treatment of Major Depressive Disorder (“ MDD ”), demonstrating a 79% remission rate from depression - - Announced positive topline resu...
2024-02-12 12:13:32 ET More on ATAI, COMPASS Pathways, etc. Compass Pathways: Psilocybin Developer A Potentially Intriguing, Contrarian Play Mind Medicine: Positive MM-120 Data Leads To Other 2024 Catalysts De-Risking Psychedelics: Compass Pathways, Cybin And Atai ...
Cybin (NYSE American: CYBN) (NEO: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options. The company has announced that the Japan Patent (“JP”) Office has granted pate...
2024-02-07 07:55:47 ET More on Cybin De-Risking Psychedelics: Compass Pathways, Cybin And Atai Cybin reports positive Phase 2 data for depression drug, files Form D with SEC Cybin announces up to $64M offering of units Seeking Alpha’s Quant Rating on C...
- Newly issued patents include protection for injectable formulations and synthesis methods for the preparation of dimethyltryptamine (“DMT”) and deuterated DMT (“dDMT”) - - Patent protection further strengthens intellectual property portfolio in the 3 rd l...
2024-01-24 09:00:41 ET Palm Beach, FL – January 24, 2024 – FN Media Group News Commentary – The coming years could see a massive shift in the U.S. government’s approach to regulating hallucinogenic drugs. Several biopharma companies are developing psy...
2024-01-23 11:40:02 ET More on Cybin De-Risking Psychedelics: Compass Pathways, Cybin And Atai Cybin reports positive Phase 2 data for depression drug, files Form D with SEC Cybin announces up to $64M offering of units Seeking Alpha’s Quant Rating on C...
Cybin (NEO: CYBN) (NYSE American: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, has received approval from the U.S. Food and Drug Administration (“FDA”) for...
News, Short Squeeze, Breakout and More Instantly...
Cybin (NYSE American: CYBN) (Cboe CA: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options for mental-health disorders, is reporting “a swell” of insider purchases followi...
Miami, Florida--(Newsfile Corp. - July 8, 2024) - Fast-moving sectors need equally fast-moving companies, a box that Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) checks, supported by a June 26th update on progress made in fiscal 2024 ending on March 31st. In its presser , Cybin highlighted k...